Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice.
about
On ceramides, other sphingolipids and impaired glucose homeostasisIncreased hepatic insulin action in diet-induced obese mice following inhibition of glucosylceramide synthaseComparative plasma lipidome between human and cynomolgus monkey: are plasma polar lipids good biomarkers for diabetic monkeys?Sphingolipids in obesity, type 2 diabetes, and metabolic disease.Correction of liver steatosis by a hydrophobic iminosugar modulating glycosphingolipids metabolism.Identification of potent and selective glucosylceramide synthase inhibitors from a library of N-alkylated iminosugars.Endoplasmic reticulum heat shock protein gp96 maintains liver homeostasis and promotes hepatocellular carcinogenesis.Ceramides as modulators of cellular and whole-body metabolismIdentification of Ganglioside GM3 Molecular Species in Human Serum Associated with Risk Factors of Metabolic SyndromeWeight loss amelioration of non-alcoholic steatohepatitis linked to shifts in hepatic ceramide expression and serum ceramide levels.Prepartum body condition score and plane of nutrition affect the hepatic transcriptome during the transition period in grazing dairy cows.Angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis activates Akt signaling to ameliorate hepatic steatosisβ-Glucosidase 2 (GBA2) activity and imino sugar pharmacology.Sphingomyelin synthase 2 activity and liver steatosis: an effect of ceramide-mediated peroxisome proliferator-activated receptor γ2 suppression.The twists and turns of sphingolipid pathway in glucose regulationThe role of sphingolipids in drug metabolism and transport.Lipidomics in vascular health: current perspectives.Ganglioside GM3 as a gatekeeper of obesity-associated insulin resistance: Evidence and mechanisms.A Next Generation Multiscale View of Inborn Errors of Metabolism.Compounds of the sphingomyelin-ceramide-glycosphingolipid pathways as secondary messenger molecules: new targets for novel therapies for fatty liver disease and insulin resistance.Development of hepatocellular carcinoma in a murine model of nonalcoholic steatohepatitis induced by use of a high-fat/fructose diet and sedentary lifestyle.Assessment of partially deoxygenated deoxynojirimycin derivatives as glucosylceramide synthase inhibitors.Inhibition of glycosphingolipid synthesis ameliorates atherosclerosis and arterial stiffness in apolipoprotein E-/- mice and rabbits fed a high-fat and -cholesterol diet.Impairment of Akt activity by CYP2E1 mediated oxidative stress is involved in chronic ethanol-induced fatty liver.β-glycosphingolipids ameliorated non-alcoholic steatohepatitis in the Psammomys obesus model.Elevated plasma sphingomyelin (d18:1/22:0) is closely related to hepatic steatosis in patients with chronic hepatitis C virus infection.Hepatic glycosphingolipid deficiency and liver function in mice.Novel Interconnections in Lipid Metabolism Revealed by Overexpression of Sphingomyelin Synthase-1.Impaired liver regeneration by β-glucosylceramide is associated with decreased fat accumulation.Control of homeostatic and pathogenic balance in adipose tissue by ganglioside GM3.FAM3A activates PI3K p110α/Akt signaling to ameliorate hepatic gluconeogenesis and lipogenesis.Sphingolipid regulators of cellular dysfunction in Type 2 diabetes mellitus: a systems overview.
P2860
Q27021446-F1506307-E241-460E-B96A-93922AA22C18Q28474576-B97825BB-80E7-4A19-80E1-8C1A76465217Q28478051-333738CF-B19E-4864-AEF9-809382CDB55AQ33880588-29E185EB-6E5D-4BBA-9442-0CBCF15D8AA6Q34440771-030B9A89-766E-4A87-B342-886B8AA454DDQ35181892-425883C6-7077-4265-A522-F5C9E7280958Q35204677-246D29C3-12C5-44D5-A456-887489F51A8AQ35484864-2A97C156-BDE0-4B8F-A65F-BED7081B2564Q35671752-64405B32-19B1-4721-A0A5-FABDDE81EA2AQ35997786-CE91353D-9747-4185-96BD-A5F53158A7F5Q36180569-264C99D5-3703-46A9-8C08-F7A9E55EEC98Q36587510-CE2DE6DE-2BFC-4A84-9250-0060E82FB15EQ37151058-3DB7DA34-1E25-4AD0-A9C7-46287963964DQ37200535-2779C9F7-0B1A-4375-9F93-CDAD984BFDA5Q37766367-1550C0EB-DD6D-4CFE-AA2D-F9EA71DFD0AAQ38071694-B824359E-17C5-4158-9547-C3C4D1140364Q38537535-793561FC-401E-433F-8626-E30263F3533AQ38598747-B92223DB-F287-4FE2-9C14-90F834E74F3FQ38681906-12CEEBDD-F82A-433A-AC31-281A2F9DB1ABQ38833111-E15EB88A-03AD-4CF5-AFF4-F11C26DBFAD2Q39102930-0D4E2FC5-D9BE-427A-84E5-AC09B8E4C75AQ39514735-2592AA65-F093-4BEC-B50E-9439D8E55781Q40578811-E4C48193-DEB1-4DC1-9233-2AB3A636C107Q42009639-34DFECB3-9955-4608-942A-CFE13E1F7E21Q42066264-73A2AF4E-1A78-4A3E-A70D-D9FD68E2A25AQ42219793-26903A79-0A58-4282-BEAB-D605ED147245Q43078747-B49E71D2-B8C9-4342-8F05-0A6478DD18BCQ48579084-AEBF3EA3-1434-4F6F-817F-C9E6A3063092Q51075878-B9BF14C1-3223-4EDE-A375-1520A847E633Q53012519-FAD7293D-D507-4D46-9380-971D29C1ACB6Q54354396-B94EF902-1187-4175-BFC4-E3692B428917Q55278796-FD8D82A9-5C47-4811-B817-4B90DCF6A196
P2860
Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Modulation of glycosphingolipi ...... ses hepatic steatosis in mice.
@en
type
label
Modulation of glycosphingolipi ...... ses hepatic steatosis in mice.
@en
prefLabel
Modulation of glycosphingolipi ...... ses hepatic steatosis in mice.
@en
P2093
P2860
P50
P356
P1433
P1476
Modulation of glycosphingolipi ...... rses hepatic steatosis in mice
@en
P2093
Albert K Groen
Carlos Vrins
Cindy P A A van Roomen
Nike Claessen
Roelof Ottenhoff
P2860
P304
P356
10.1002/HEP.23175
P407
P577
2009-11-01T00:00:00Z